Probes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
MET gene amplification, as detected by FISH, is one mechanism of MET overexpression. MET amplifications are detected in 3-7% of non-small cell lung cancer (NSCLC) and associated with resistance to EGFR inhibitors and shorter survival in this disease. MET amplifications are also detected in a wide variety of other solid tumors including gastric (up to 10%), esophageal (4%), and endometrial tumors. Clinical trials have demonstrated activity of MET inhibitors against numerous solid tumors such as lung, breast, melanoma, liver, prostate, renal, and ovarian, including tumor reduction in NSCLC and breast cancer patients who had developed resistance to EGFR inhibitors.
Storage and Transportation
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.